[Cardioprotective and cardio-reparative drugs].
The left ventricular hypertrophy is a deleterious consequence of the arterial hypertension, recognized as independent risk factor. The left ventricular hypertrophy has a myocytic component, of hemodynamic origin, where all the antihypertensive treatments known would be active, in greater or smaller degree, and it's been demonstrated the benefit of the intervention in the sense of the fact that exist improvement indications of the morbi-mortality (cardio-protection). The left ventricular hypertrophy has at the same time a fibrotic component, of neuro-hormonal origin that can be reversed (cardio-reparation) fundamentally by influence of the ACEIs, that would improve furthermore all the components of the called "hypertensive syndrome".
Bolaños
F
F
Unidad de Cardiología, Hospital General de Igualada, Barcelona.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D013577:Syndrome
D000806:Angiotensin-Converting Enzyme Inhibitors